Ultima Genomics improves human health through advanced genomic sequencing technologies, processing large amounts of genetic data to provide insights into biology and diseases. Its unique sequencing architecture allows for extensive data collection, detection of small genetic variations, and routine testing for early disease detection. This capability gives clients, including researchers and healthcare providers, access to high-quality genomic information. The company's goal is to continuously innovate and expand its capabilities to help clients achieve significant advancements in understanding and treating diseases.

D1 Capital Partners

General Atlantic

aMoon Fund

Marius Nacht

Founders Fund

Andreessen Horowitz

Playground Global

Lightspeed

Khosla Ventures

National Human Genome Research Institute

National Institutes of Health

Biotechnology

Healthcare

Ultima Genomics

Myriad Genetics has announced a collaboration with Ultima Genomics to evaluate the potential of the UG 100 sequencing platform and ppmSeq technology in advancing clinical tests in oncology and reproductive genomics.

Myriad and Ultima to study UG 100 sequencing platform for genomics clinical tests

What You Should Know:– Hartwig Medical Foundation, a provider in using comprehensive genetic profiling to improve cancer treatment, and Ultima Genomics, a developer of groundbreaking next-generation sequencing (NGS) technology, announce a groundbreaking collaboration.– The strategic partnership aims to make whole genome sequencing, the most detailed form of genetic analysis, a more accessible and affordable tool in the fight against cancer.The Challenge: High Costs Limit TestingDespite advancements in NGS technology, the high cost often restricts its use in cancer testing, particularly whole genome sequencing. This limits the depth and frequency of testing, hindering the development of personalized treatment plans for cancer patients.Introducing Ultima’s UG 100 System and ppmSeq TechnologyUltima Genomics addresses this challenge with the UG 100 sequencing system and ppmSeq technology.UG 100 System: This innovative platform offers significantly lower sequencing costs compared to traditional technologies.This innovative platform offers significantly lower sequencing costs compared to traditional technologies. ppmSeq Technology: This unique technology delivers ultra-high accuracy for detecting single nucleotide variants (SNVs) in a patient’s genetic makeup.Benefits of the CollaborationBy combining these advancements, Hartwig and Ultima aim to:Increase Accessibility: Make whole genome-based cancer diagnostics more affordable for patients, enabling more informed treatment decisions.Make whole genome-based cancer diagnostics more affordable for patients, enabling more informed treatment decisions. Enhanced Monitoring: Enable more frequent monitoring of a patient’s cancer, allowing for timely adjustments to treatment plans.Enable more frequent monitoring of a patient’s cancer, allowing for timely adjustments to treatment plans. Minimal Residual Disease Detection: Explore the potential for using the UG 100 system to detect minimal residual disease (MRD) in a patient’s blood. MRD refers to the presence of a small number of cancer cells remaining after treatment.Collaboration for Future AdvancementsHartwig Medical Foundation plans to integrate the UG 100 system and ppmSeq technology into their routine diagnostic procedures, working with partner hospitals

Hartwig Medical, Ultima Genomics Partner To Transform Precision Oncology With Affordable Genetic Testing

FREMONT, Calif. AMSTERDAM--(BUSINESS WIRE)--Hartwig Medical Foundation, a pioneer in deploying complete genomic profiling to improve oncology outcomes, and Ultima Genomics, a developer of a revolutionary new ultra-high throughput next-generation sequencing (NGS) architecture, today announced the deployment of Ultima’s UG 100 sequencing system and its proprietary ppmSeq technology for improving precision oncology testing and research. This collaboration aims to reduce test costs and make complete genome-based cancer diagnostics accessible for more patients to have better informed cancer treatment. In parallel, platform strengths will be explored for minimal residual disease detection in blood of cancer patients with a one-size-fits-all solution that builds on pre-existing complete tumor profile information. Despite significant advancements in cancer diagnosis and treatment enabled by next-generation sequencing technology, the relatively high costs of existing sequencing technologies limit the depth, breadth, and frequency of sequencing use in cancer testing, especially for whole genome sequencing-based approaches. In February 2024, Ultima launched its first commercial system, the UG 100TM, which deploys a novel sequencing architecture that provides significantly lower-cost sequencing compared to conventional technologies

Hartwig And Ultima Genomics Collaborate To Reduce Costs For Whole Genome Cancer Profiling, Minimal Residual Disease Testing And Generating Genetic Data At Scale

FREMONT, Calif.--(BUSINESS WIRE)--Ultima Genomics, Inc., a developer of a revolutionary new ultra-high throughput sequencing architecture, today announced the full commercial availability of the UG 100TM sequencer. The UG 100TM system, Ultima’s first commercial product, leverages Ultima’s unique sequencing architecture featuring an open silicon wafer substrate to replace the traditional flow cells and enable the $100 genome and beyond.“Our goal when designing our sequencing architecture and the UG 100TM was to provide a technology platform that enables a scalable roadmap beyond the $100 genome, ultra-high output without the limitations of batching, and extreme accuracy in applications for which it is most needed,” said Gilad Almogy, founder and CEO of Ultima Genomics. “We are excited to be launching the UG 100TM and helping the genomics community usher in the era of the $100 genome and beyond.”The UG 100TM system – now commercially availableThe UG 100TM, now available for purchase, features Ultima’s proprietary wafer-based sequencing substrate with flexible, non-kit-based sequencing reagent cartridges and a novel sequencing chemistry. Unlike more traditional kit-based approaches, this unique architecture allows for built-in robotics enabling full 24/7 run automation for improved flexibility with limited user touchpoints. The UG 100TM system also leverages recent advancements in machine learning to improve base calling and variant calling algorithms for improved accuracy and performance.Select key features of the UG 100 system include:Low cost reagents. One wafer and reagent configuration at a price of $2,000 delivers 6-8 B reads and an expected average read length of 300 base pairs, or an output of up to 2.4 Tb per wafer

Ultima Announces Ug 100™ And Reveals Disruptive Cost And Accuracy Profile To Enable The Era Of The $100 Genome And Beyond

FREMONT, Calif.--(BUSINESS WIRE)--Ultima Genomics, Inc., a developer of a revolutionary new ultra-high throughput sequencing architecture, will present product and commercial launch details for the UG 100™ system as the Gold Sponsor at the Advances in Genome Biology and Technology (AGBT) General Meeting Feb. 5-8, 2024, in Orlando, FL. The Gold Sponsor workshop will also include presentations by customers and collaborators from multiple leading institutions including:Stacey Gabriel, Ph.D., Executive Vice President of Platforms and Scientific Execution, Institute Scientist, Broad Institute of MIT and HarvardAziz Al’Khafaji, Ph.D., Associate Director, Technology Development – Genomics Platform, Broad Institute of MIT and HarvardRahul Satija, D.Phil., Core Faculty Member, New York Genome CenterWill Salerno, Ph.D., Executive Director of Genome Informatics  Data Engineering, Regeneron PharmaceuticalsDan Landau, M.D., Ph.D., Professor of Physiology and Biophysics, Weill Cornell Medical CollegeJoin Ultima for a series of talks and poster sessions, including:. Monday, February 6:

Ultima Genomics To Launch Ug 100™ System And Present Data At Agbt

The Genomic And Multi-omic RevolutionThe first human genome decoding started in 1990 and was first achieved in 2003. It also cost a staggering $3B.Fast forward 20 years, and the cost of genome sequencing has fallen to $600/genome. Or a 5,000,000x reduction in cost! And it could fall to as little as $200.This completely changed the way we approach genomics from a medical perspective. Not only does it allow for a massive amount of data to be created and analyzed, but also for each person to potentially have access to advanced personalized medicine, matching his unique genetic makeup.With genomics turning into a basic medical amenity, genome sequencing companies will benefit from a quickly growing market, and a growing number of applications, from nutrition and aging prevention to early cancer detection.And this is not all. The same technology that was used to do the sequencing of the genome's DNA can also be used to create whole new scientific fields:Metagenomics: sequencing the genome of the bacteria that live in our guts and have a huge impact on our health.Transcriptomes  Epigenetics: if the genome is the blueprint, the transcriptomes are how the blueprint is used in practice and in real-time. This is likely to be very relevant for solving many uncurable diseases and metabolic problems.Agrigenomics: using genomics to improve agricultural yields and farm animal productivity.Ecological studies: evaluating accurately the health of an ecosystem and its genetic diversity.Synthetic Biology: The creation of new genes, traits, or entire organisms with a specific purpose: for example, plastic-eating bacteria or biofuel-producing algae.5 Best Genome Sequencing CompaniesThis article covers the 5 best publicly traded genome sequencing companies

5 Best Genome Sequencing Companies

BURLINGTON, N.C., and FREMONT, Calif., July 29, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced an expanded collaboration with Ultima Genomics to utilize its UG 100TM sequencing solution and ppmSeqTM technology to explore new whole genome sequencing (WGS) clinical applications, including molecular residual disease (MRD) in patients with early-stage solid tumor cancers.Labcorp recently introduced Labcorp® Plasma Detect™, the first clinically validated, tumor-informed, WGS-based circulating tumor DNA (ctDNA) MRD solution for research and investigational use. Labcorp intends to use Ultima's UG 100 platform and ppmSeq technology, which, combined with Plasma Detect, have demonstrated in preliminary data the ability to detect rare variants at extremely low limits, improved sensitivity and specificity, and more efficient, scalable and cost-effective workflows."By combining Labcorp's leadership, testing capabilities and expansive network with the accuracy, scalability and cost-effectiveness of Ultima's technology, we can help transform oncology testing for pathologists, oncologists and our biopharmaceutical partners," said Shakti Ramkissoon, M.D., Ph.D., MBA, vice president, medical lead for oncology at Labcorp. "Through this collaboration, Labcorp aims to drive increased efficiency, scalability and cost-effectiveness while improving access to affordable genetic testing in emerging areas with significant unmet need.""We look forward to expanding our collaboration with Labcorp to explore the use of our technology in the fast-growing clinical areas of MRD and clinical WGS," said Gilad Almogy, CEO of Ultima Genomics. "At Ultima, we developed our unique sequencing architecture to specifically meet the needs of large-scale applications. The ability to be accurate at extremely low limits of detection with our ppmSeq technology and extreme sequencing depth will be transformational for oncology testing and applications such as cell-free DNA."This relationship follows other strategic collaborations Labcorp has established to improve patient and provider access to and affordability for innovative technologies.About LabcorpLabcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities

Labcorp Expands Collaboration With Ultima Genomics To Advance Whole Genome Sequencing Applications And Oncology Testing Capabilities

FREMONT, Calif., Aug. 13, 2024 /PRNewswire/ -- Ultima Genomics, a developer of an innovative new ultra-high throughput sequencing architecture, today announced the addition of two industry leaders focused on driving operational excellence and commercial adoption. The appointments follow the strong uptake of Ultima's technology in clinical applications and will accelerate the Company's path towards expanded clinical utilization as well as support commercial efforts broadly. Chris Seipert. Lara Toerien

Ultima Genomics Adds Tenured Leadership To Drive Operational Excellence And Commercial Adoption

FREMONT, Calif.--(BUSINESS WIRE)--Ultima Genomics, Inc., a developer of a revolutionary new ultra-high throughput sequencing architecture, today announced the launch and full commercial availability of the UG 100™ at the upcoming Advances in Genome Biology and Technology (AGBT) conference on February 5, 2024. The UG 100™ system, Ultima’s first commercial product, leverages a unique sequencing architecture featuring an open silicon wafer to replace multiple traditional flow cells and enable the $100 genome and beyond. The UG 100™ is an ultra-high throughput system purposefully built for high-volume applications. The system features full 24/7 run automation, flexibility for smaller and significantly faster runs, high accuracy for germline applications and an extreme accuracy mode for somatic applications and rare event detection. “After much anticipation, we are excited to publicly announce the full commercial availability of the $100 genome at the upcoming AGBT conference in February,” said Gilad Almogy, Founder and CEO of Ultima. “When we designed our new sequencing technology, we took on the considerable challenge of creating an entirely new architecture that addressed key shortcomings faced by sequencers today

Ultima Genomics Announces End Of Early Access And Upcoming Launch Of Ug 100™

World's Most Comprehensive Protein Study Highlights Ultima's Commitment to Unlocking the Power of Genomics at ScaleFREMONT, Calif., Jan. 9, 2025 /PRNewswire/ -- Ultima Genomics, Inc., a developer of an ultra-high throughput next-generation sequencing (NGS) platform, today announced that its UG 100™ was selected as the sequencing platform to enable UK Biobank's unprecedented protein study, which will be the world's largest and most comprehensive proteomics study to date. The UG 100™ was selected by a consortium of 14 leading biopharma companies funding the UK Biobank Pharma Proteomics Project and will be used in conjunction with Thermo Fisher Scientific's Olink® Explore HT proteomics platform to play a central role in this first-of-its-kind effort in understanding disease progression and advancing personalized medicine. This unparalleled project aspires to quantify more than 5,400 protein markers across 600,000 samples, including those from half a million UK Biobank participants and 100,000 second samples taken from a subset of these participants across different time points (spanning up to 15 years). This will allow researchers to explore a unique and unprecedented database. The UK Biobank project, announced today, aims to investigate how fluctuations in protein levels during mid- to late-life may influence disease progression and overall health

Ultima Genomics Announces Ug 100™ Sequencing Platform Selected For Uk Biobank'S Groundbreaking Human Proteome Study

High-throughput genomic sequencing services

Ultima Genomics

High-throughput genomic sequencing services

Ultima Genomics

High-throughput genomic sequencing services

About

Simplify's Take

What believers are saying

What critics are saying

What makes Ultima Genomics unique

6 month growth

1 year growth

2 year growth

Benefits

Recently Posted Jobs

Ultima Genomics is Hiring for 0 Jobs on Simplify!